Eli Lilly's Foundayo Outperforms Semaglutide in Weight Loss and A1C Reduction

New Evidence on Weight Loss Treatments for Type 2 Diabetes

Eli Lilly and Company's recent findings introduce significant advancements in the treatment of type 2 diabetes, showcasing the effectiveness of Foundayo (orforglipron) 17.2 mg. This treatment appears to offer superior outcomes in weight loss and A1C reduction when measured against oral semaglutide 25 mg over a span of 52 weeks. Such insights stem from a detailed indirect treatment comparison that leverages data from both the ACHIEVE-3 and PIONEER PLUS studies.

Study Overview

This analysis, presented at the prestigious 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, emphasizes the potential of Foundayo in revolutionizing the management of type 2 diabetes. According to Dr. Deborah Horn, a leading authority in obesity medicine, the choice of medication can profoundly influence the daily lives of individuals managing this condition. The availability of comparative data is essential in facilitating tailored treatment plans to meet individual patient needs.

In the indirect comparison, individuals receiving Foundayo 17.2 mg achieved an average weight loss of 1.5% more than those taking oral semaglutide 25 mg, alongside a 0.3% reduction in A1C. Notably, this effectiveness was consistent across various statistical analyses, indicating that Foundayo could deliver weight loss between 1.5% and 2.4% and A1C reductions from 0.3% to 0.6% when compared to the oral medication.

Findings from ACHIEVE-3

The ACHIEVE-3 trial, which involved nearly 1,700 participants across several countries, sought to evaluate the safety and efficacy of Foundayo against oral semaglutide in adults whose diabetes was inadequately controlled with metformin. The trial demonstrated that participants on Foundayo lost an average of 19.7 lbs (9.2%) compared to only 11.0 lbs (5.3%) for those on the higher semaglutide dose. Moreover, A1C levels dropped by an average of 2.2% for Foundayo users versus 1.4% for the counterparts on semaglutide.

The Implications of These Findings

The implications of these findings are vast. As articulated by Rachel Batterham, senior vice president of medical innovation at Lilly, while traditional head-to-head trials provide critical data, indirect comparisons like this offer valuable insights until more definitive trials can be completed. Foundayo’s administration method, which does not impose fasting or water restrictions, further establishes its potential as a cornerstone medication for many adults grappling with type 2 diabetes.

About Foundayo

FDA-approved for adults grappling with obesity or those affected by weight-related medical issues, Foundayo aims to assist individuals in shedding excess body weight and maintaining that weight loss effectively when coupled with a reduced-calorie diet and increased activity levels. As a once-daily oral glucagon-like peptide-1 receptor agonist, it can be taken at any time without dietary constraints. Originally discovered by Chugai Pharmaceutical Co., Foundayo was licensed by Eli Lilly in 2018 and is also being explored for various other conditions, including hypertension and obstructive sleep apnea.

Conclusion

The data on Foundayo represents a pivotal shift in the treatment paradigm for type 2 diabetes, encouraging more personalized approaches based on the unique profiles of individual patients. As the medical community continues to observe these developments, the hope is that tools like Foundayo can lead to improved health outcomes and a better quality of life for those managing type 2 diabetes.

For further details regarding the ACHIEVE-3 program, you can refer to the comprehensive results shared through various publications and sources associated with Eli Lilly.